Last reviewed · How we verify
Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes
This study is not being conducted in the United States. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to gliclazide in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.
Details
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 1092 |
| Start date | 2005-01 |
Conditions
- Diabetes Mellitus, Type 2
Interventions
- vildagliptin
- Gliclazide
Primary outcomes
- Change from baseline in HbA1c at 104 weeks — 104 weeks
Countries
Germany, Switzerland